Groundbreaking Collaboration: Vivos Therapeutics and Cellev8 Nutrition Join Forces to Address Sleep Apnea and Oxidative Stress
Cellev8 Nutrition (OTC Pink:CELV) and Vivos Therapeutics announced a strategic joint marketing venture to address obstructive sleep apnea (OSA) and oxidative stress. The collaboration combines Vivos' FDA-cleared oral medical devices for treating OSA with Cellev8's SOD2-based nutraceutical gummies.
The venture targets a significant market, with an estimated 80 million American adults and 10 million children affected by sleep apnea, with up to 80% undiagnosed. The partnership aims to provide a comprehensive solution through Cellev8's nutraceutical products, which have shown efficacy in reducing oxidative stress, inflammation, and improving metabolic health in clinical trials.
The collaboration offers a complementary approach where Vivos devices restore airways while Cellev8's products support bodily rejuvenation and recovery from OSA-related damage.
Cellev8 Nutrition (OTC Pink:CELV) e Vivos Therapeutics hanno annunciato una collaborazione strategica nel marketing per affrontare l'apnea ostruttiva del sonno (OSA) e lo stress ossidativo. Questa collaborazione unisce i dispositivi medici orali approvati dalla FDA di Vivos per il trattamento dell'OSA con le caramelle nutrizionali a base di SOD2 di Cellev8.
Il progetto si rivolge a un mercato significativo, con circa 80 milioni di adulti americani e 10 milioni di bambini colpiti da apnea del sonno, di cui fino all'80% non diagnosticati. L'obiettivo della partnership è fornire una soluzione completa attraverso i prodotti nutraceutici di Cellev8, che hanno dimostrato efficacia nella riduzione dello stress ossidativo, dell'infiammazione e nel miglioramento della salute metabolica negli studi clinici.
La collaborazione offre un approccio complementare in cui i dispositivi di Vivos ripristinano le vie aeree, mentre i prodotti di Cellev8 sostengono il ringiovanimento del corpo e la ripresa dai danni correlati all'OSA.
Cellev8 Nutrition (OTC Pink:CELV) y Vivos Therapeutics anunciaron una asociación estratégica de marketing para abordar la apnea obstructiva del sueño (OSA) y el estrés oxidativo. La colaboración combina los dispositivos médicos orales aprobados por la FDA de Vivos para tratar la OSA con los gomitas nutracéuticas a base de SOD2 de Cellev8.
La iniciativa se dirige a un mercado significativo, con aproximadamente 80 millones de adultos estadounidenses y 10 millones de niños afectados por la apnea del sueño, de los cuales hasta el 80% no están diagnosticados. La asociación tiene como objetivo proporcionar una solución integral a través de los productos nutracéuticos de Cellev8, que han demostrado eficacia en la reducción del estrés oxidativo, la inflamación y la mejora de la salud metabólica en ensayos clínicos.
La colaboración ofrece un enfoque complementario donde los dispositivos de Vivos restauran las vías respiratorias mientras que los productos de Cellev8 apoyan la rejuvenecimiento del cuerpo y la recuperación de los daños relacionados con la OSA.
Cellev8 Nutrition (OTC Pink:CELV)과 Vivos Therapeutics는 폐쇄성 수면 무호흡증(OSA)과 산화 스트레스 문제를 해결하기 위한 전략적 공동 마케팅 협력을 발표했습니다. 이 협력은 OSA 치료를 위한 Vivos의 FDA 승인 구강 의료 기기와 Cellev8의 SOD2 기반 영양 보충 젤리를 결합합니다.
이 사업은 약 8천만 명의 미국 성인과 1천만 명의 아동이 수면 무호흡증에 영향을 받고 있으며 최대 80%가 진단되지 않고 있는 상당한 시장을 목표로 하고 있습니다. 파트너십은 Cellev8의 영양 보충 제품을 통해 포괄적인 솔루션을 제공하는 것을 목표로 하며, 이 제품은 임상 시험에서 산화 스트레스, 염증 감소 및 대사 건강 개선에 효과가 있는 것으로 나타났습니다.
이 협력은 Vivos의 기기가 기도를 복원하는 동시에 Cellev8의 제품이 OSA 관련 손상으로부터 신체 회복과 젊음을 지원하는 보완적 접근 방식을 제공합니다.
Cellev8 Nutrition (OTC Pink:CELV) et Vivos Therapeutics ont annoncé une collaboration stratégique en marketing pour traiter l'apnée obstructive du sommeil (OSA) et le stress oxydatif. Cette collaboration associe les dispositifs médicaux buccaux approuvés par la FDA de Vivos pour traiter l'OSA avec les gommes nutraceutiques à base de SOD2 de Cellev8.
Ce projet vise un marché significatif, avec environ 80 millions d'adultes américains et 10 millions d'enfants touchés par l'apnée du sommeil, dont jusqu'à 80 % ne sont pas diagnostiqués. L'objectif du partenariat est de fournir une solution complète grâce aux produits nutraceutiques de Cellev8, qui ont montré leur efficacité dans la réduction du stress oxydatif, de l'inflammation et l'amélioration de la santé métabolique lors d'essais cliniques.
La collaboration offre une approche complémentaire où les dispositifs de Vivos restaurent les voies respiratoires tandis que les produits de Cellev8 soutiennent le rajeunissement du corps et la récupération des dommages liés à l'OSA.
Cellev8 Nutrition (OTC Pink:CELV) und Vivos Therapeutics haben ein strategisches gemeinsames Marketingunternehmen zur Bekämpfung von obstruktiver Schlafapnoe (OSA) und oxidativem Stress angekündigt. Die Zusammenarbeit kombiniert die von der FDA zugelassenen oralen Medizinprodukte von Vivos zur Behandlung von OSA mit den SOD2-basierten nutraceutical Gummis von Cellev8.
Das Vorhaben richtet sich an einen erheblichen Markt, in dem schätzungsweise 80 Millionen amerikanische Erwachsene und 10 Millionen Kinder von Schlafapnoe betroffen sind, wobei bis zu 80% undiagnostiziert bleiben. Partnerschaft zielt darauf ab, eine umfassende Lösung durch die nutraceutical Produkte von Cellev8 bereitzustellen, die sich in klinischen Studien als wirksam bei der Reduzierung von oxidativem Stress, Entzündungen und der Verbesserung der Stoffwechselgesundheit erwiesen haben.
Die Zusammenarbeit bietet einen komplementären Ansatz, bei dem die Vivos-Geräte die Atemwege wiederherstellen, während die Produkte von Cellev8 die körperliche Erneuerung und Erholung von OSA-bedingten Schäden unterstützen.
- Strategic partnership targeting large market of 90 million potential US customers
- Complementary product offering combining FDA-cleared devices with nutraceuticals
- Clinical trials demonstrate efficacy of Cellev8's products in multiple health aspects
- None.
WELLINGTON, FL and HIGHLANDS RANCH, CO / ACCESSWIRE / December 10, 2024 / Cellev8 Nutrition Inc. (OTC Pink:CELV) and Vivos Therapeutics, Inc. today announced a strategic joint marketing venture aimed at providing comprehensive solutions for patients with obstructive sleep apnea (OSA) and associated oxidative stress. This collaboration combines Vivos Therapeutics' FDA-cleared oral medical devices for treating moderate to severe OSA in children and adults with Cellev8 Nutrition's proprietary gummy form of nutraceuticals featuring the powerful enzymatic antioxidant, SOD2, designed to mitigate oxidative stress in the body.
Addressing a Significant Health Concern
Eli Lilly recently estimated that approximately 80 million American adults suffer from sleep apnea. On top of that, an estimated 10 million children also suffer. The prevalence is particularly high among older adults, with up to
The Complex Relationship Between Sleep Apnea, Oxidative Stress and Inflammation
The relationship between sleep apnea and weight is complex and bidirectional:
Obesity as a Risk Factor: Obesity is recognized as one of the most important reversible risk factors for obstructive sleep apnea. Studies suggest that obesity is a major factor in
41% of adult OSA cases, including58% of moderate-to-severe cases.Impact of Weight Loss: Weight loss has been shown to improve sleep apnea severity. A 5
-10% reduction in body weight can significantly improve OSA symptoms. Some studies suggest that a10% weight loss is associated with a26% reduction in the number of apnea events during sleep.
The interplay between weight and sleep apnea underscores the importance of addressing both issues concurrently for effective management and improved health outcomes.
Comprehensive, Natural Approach to Health Management
This collaboration intends to provide an all-natural, scientifically-backed solution through Cellev8 Nutrition's comprehensive lineup of nutraceutical products. The range includes Inflammation and Recovery, Focus and Memory, and the newly introduced SlimCell formulations.Cellev8 Nutrition's proprietary blend of clinically proven ingredients has demonstrated significant efficacy in addressing multiple aspects of health:
Oxidative Stress Reduction: The formulations have shown a measurable decrease in markers of oxidative stress, a key factor in various chronic conditions including OSA. Importantly, Cellev8 can mitigate the oxidative damage done before and during the OSA treatment that Vivos delivers.
Long-term Benefits: Even after the permanent improvement sustained by Vivos treatment, Cellev8's nutraceuticals continue to aid in managing other chronic inflammatory causes, providing ongoing support for overall health.
Anti-Inflammatory Effects: Clinical studies have indicated a reduction in systemic inflammation, which is crucial for overall health and particularly relevant for OSA patients.
Cognitive Enhancement: The Focus and Memory gummies have demonstrated improvements in various cognitive functions, including attention, memory recall, and processing speed.
Metabolic Health: The SlimCell product line has shown promising results in weight management, with statistically significant reductions in Body Mass Index (BMI) observed in clinical trials.
Body Composition Improvements: Participants in studies have experienced reductions in hip and waist circumferences, as well as a decrease in the appearance of cellulite, attributed to the anti-inflammatory properties of the formulations.
These benefits have been observed in controlled studies over periods of 30, 60, and 90 days of daily use, suggesting both short-term and sustained positive effects.
Complementary Approach to Treatment
Kirk Huntsman, CEO of Vivos Therapeutics, elaborated on the partnership's potential: "This joint venture enables us to offer a complementary product to help ameliorate the severe damage caused to virtually every major bodily system in OSA patients. Our Vivos treatment does a great job of restoring an airway, while Cellev8 Nutrition products can help the rest of the body rejuvenate and recover. We can easily see a large portion of our patients taking these products as an important part of their healing process."
Mike Ferraro, CEO of Cellev8 Nutrition, provided additional context: "With as many as 90 million U.S. children and adults having OSA, and prevalence rising to over
Innovative Approach to OSA Management
This collaboration represents a novel, multifaceted approach to addressing both the physical obstruction and oxidative stress associated with OSA. By combining Vivos Therapeutics' device-based treatment with Cellev8 Nutrition's SOD2 based supplements, this partnership aims to provide patients with a more comprehensive solution to manage their conditions.
About the Companies
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA).
Cellev8 Nutrition Inc. (OTC Pink:CELV) specializes in developing innovative nutraceutical products, including their proprietary SOD2-delivering gummy designed to combat oxidative stress.
This strategic partnership has the potential to significantly impact the landscape of OSA treatment, offering patients a more holistic approach to managing this prevalent and serious health condition.
FDA Disclaimer:These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Forward-Looking Statements Disclaimer: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements may include, but are not limited to, statements regarding future business activities including the expansion into new markets, future collaborations, future product development, and potential future revenue. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from those contemplated by the forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, uncertainties inherent in the development and commercialization of potential products, uncertainty in the timing of regulatory approvals, changes in the financial markets, regulatory actions, changes in healthcare systems, competitive conditions, and other risks described in our SEC filings. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Contact Information
Michael Ferraro
CEO
mike@cellev8.com
561-578-0000
SOURCE: Cellev8 Nutrition Inc
View the original press release on accesswire.com
FAQ
What is the purpose of Cellev8 Nutrition (CELV) and Vivos Therapeutics partnership?
How many people could benefit from Cellev8 (CELV) and Vivos' joint venture?
What products will Cellev8 (CELV) offer through this partnership?
